• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical-features analysis on 926 patients with virological breakthrough in chronic hepatitis B receiving nucleos(t)ide analogues.

作者信息

Huang Cheng, Yang Xiang-Hui, Yang You-Lan, Huang Ai-Long, Shi Xiao-Feng

机构信息

Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Department of Infectious Diseases and Institute for Virus Hepatitis, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Department of Infectious Diseases and Institute for Virus Hepatitis, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; Department of Infectious Diseases of the Ninth People's Hospital of Chongqing Province, Chongqing, China.

出版信息

Eur J Intern Med. 2018 Jul;53:e9-e10. doi: 10.1016/j.ejim.2018.02.014. Epub 2018 May 24.

DOI:10.1016/j.ejim.2018.02.014
PMID:29803607
Abstract
摘要

相似文献

1
Clinical-features analysis on 926 patients with virological breakthrough in chronic hepatitis B receiving nucleos(t)ide analogues.926例接受核苷（酸）类似物治疗的慢性乙型肝炎病毒学突破患者的临床特征分析
Eur J Intern Med. 2018 Jul;53:e9-e10. doi: 10.1016/j.ejim.2018.02.014. Epub 2018 May 24.
2
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.用于乙型肝炎病毒的核苷（酸）类似物：长期成功的策略
Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92. doi: 10.1016/j.bpg.2008.11.003.
3
Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.对拉米夫定耐药的慢性乙型肝炎患者进行长达5年的长期阿德福韦酯单药治疗。
Antivir Ther. 2010;15(2):235-41. doi: 10.3851/IMP1510.
4
Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.长期拉米夫定联合阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎患者的临床过程及病毒学应答的预测因素。
J Med Virol. 2011 Jun;83(6):953-61. doi: 10.1002/jmv.22025.
5
[The clinical study of adding on adefovir dipivoxil to treat for lamivudine resistant patients with chronic hepatitis B].[加用阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎患者的临床研究]
Zhonghua Gan Zang Bing Za Zhi. 2009 May;17(5):387-8.
6
Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.替比夫定治疗阿德福韦酯治疗应答不佳的 HBeAg 阳性慢性乙型肝炎患者的疗效。
J Viral Hepat. 2013 Apr;20 Suppl 1:46-51. doi: 10.1111/jvh.12063.
7
Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.在阿德福韦酯应答不完整的患者中，接受替诺福韦/恩曲他滨联合治疗或替诺福韦单药治疗时，乙型肝炎病毒准种的相似演变。
J Hepatol. 2013 Oct;59(4):684-95. doi: 10.1016/j.jhep.2013.05.038. Epub 2013 Jun 3.
8
Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.替比夫定联合阿德福韦酯治疗拉米夫定耐药或病毒学突破的慢性乙型肝炎患者。
Eur J Gastroenterol Hepatol. 2013 Jul;25(7):814-9. doi: 10.1097/MEG.0b013e32835ee516.
9
Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.拉米夫定耐药的乙型肝炎患者中阿德福韦酯和拉米夫定联合治疗的四年研究：乙型肝炎病毒基因型和耐药突变模式的影响。
J Viral Hepat. 2011 Mar;18(3):206-15. doi: 10.1111/j.1365-2893.2010.01301.x.
10
Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B.阿德福韦酯添加拉米夫定挽救治疗对拉米夫定耐药慢性乙型肝炎患者的部分病毒学应答。
Digestion. 2013;87(3):196-203. doi: 10.1159/000348853. Epub 2013 May 9.

引用本文的文献

1
Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2.目前用于治疗单纯疱疹病毒 1 型和 2 型感染的药物。
Viruses. 2021 Jun 25;13(7):1228. doi: 10.3390/v13071228.